Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Year: 2022
Type: article
Study design: Observational Study
Source: Melanoma Research
Authors: Jessica Louise Smith, Alexander M. Menzies, Justine V. Cohen, Margarida Mut-Lloret, Alpaslan Ozgun, Lavinia Spain, John Park, Henry T. Quach, Lalit Pallan, Jennifer McQuade, Sophie Feng, Shahneen Sandhu, Victoria Atkinson, Katy Tsai, Georgina V. Long, James Larkin, Zeynep Eroglu, Douglas B. Johnson, Ryan Sullivan, Geoffrey K. Herkes, Andrew Henderson, Matteo S. Carlino
Institutions: Westmead Hospital, The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, Mater Hospital, Massachusetts General Hospital, Peter MacCallum Cancer Centre, Moffitt Cancer Center, Royal Marsden NHS Foundation Trust, Vanderbilt University, Vanderbilt-Ingram Cancer Center, The University of Texas MD Anderson Cancer Center, Princess Alexandra Hospital, University of California, San Francisco, Blacktown & Mount Druitt Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4297259272